Allogeneic Stem Cell Transplantation Case Conference 2025-2026

RSSAAPAACPECMECNESafetyPSRM - Patient Safety/Risk Management

Add to Calendar Allogeneic Stem Cell Transplantation Case Conference 2025-2026 1/30/2025 1:00:00 PM 1/30/2025 2:00:00 PM America/New_York For More Details: https://upenn.cloud-cme.com/course/courseoverview?EID=91326 Description: This is a Weekly Case Conference whose primary goal is to provide ongoing educational updates and reviews to our physicians, nurses, PA's, pharmacists, and other professional in hematology, medical oncology and pathology staff to ensure that we are all current with the best practices of allogeneic stem cell transplantation. This series addresses clinical care in transplantation and novel cellular thera... PCAM 12 South Conference Romm 12-122 & Virtual false MM/DD/YYYY


Occurs weekly every Thursday starting on 1/30/2025 at 1:00 PM
Thursday, January 30, 2025, 1:00 PM - 2:00 PM, PCAM 12 South Conference Romm 12-122 & Virtual, Philadelphia, PA


This is a Weekly Case Conference whose primary goal is to provide ongoing educational updates and reviews to our physicians, nurses, PA's, pharmacists, and other professional in hematology, medical oncology and pathology staff to ensure that we are all current with the best practices of allogeneic stem cell transplantation. This series addresses clinical care in transplantation and novel cellular therapies is discussed. This series will promote application of the best possible and most up to date therapies and will ensure standardization across our group and minimize variations in care.


Specialties - INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - Blood Banking/Transfusion Medicine


Objectives

After completing this activity, participants should be able to:


  1. Discuss novel therapies for Graft-versus-host disease (GVHD)
  2. Discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors.
  3. Describe how to form an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
  4. Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS.
  5. Describe manifestations of immune effector cell toxicities
  6. Discuss best practices for long term follow-up and survivorship issues after allogeneic BMT
  7. Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.


In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit



AMA PRA Category 1 Credits™ (1.00 hours), ACPE (1.00 hours), American Academy of Physician Assistants (1.00 hours), NCPD Hours (ANCC) (1.00 hours), Non-Physician Attendance / Participation (1.00 hours), Patient Safety/Risk Management PSRM (1.00 hours)